Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto. - Chow V; Zhou M; Mytych DT; Colbert A; Miller MJ; Wala I; Sabet A; Radziszewski W (Pharmacology research & perspectives, 2026)